Financial HealthThe company has a substantial cash reserve, with cash, cash equivalents, and marketable securities expected to fund operations well into the future.
Product Pipeline DevelopmentUniQure expects to provide an interim update from the ongoing Phase 1/2 trials which may support a collaboration ahead of a potential pivotal program.
Regulatory MilestonesInitial FDA discussions for AMT-130 are projected, which may clarify the pathway for its potential approval and commercialization.